Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Investing Activities (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Cash from Investing Activities for 4 consecutive years, with $167.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 162.11% to $167.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $174.6 million, a 175.61% increase, with the full-year FY2025 number at $174.6 million, up 175.61% from a year prior.
  • Cash from Investing Activities was $167.5 million for Q4 2025 at Day One Biopharmaceuticals, up from $13.5 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $167.5 million in Q4 2025 to a low of -$269.6 million in Q4 2024.
  • A 4-year average of -$11.4 million and a median of $6.7 million in 2022 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 1474.66% in 2023; the steepest drop was 74520.0% in 2023.
  • Day One Biopharmaceuticals' Cash from Investing Activities stood at -$2.2 million in 2022, then surged by 1474.66% to $30.4 million in 2023, then tumbled by 987.56% to -$269.6 million in 2024, then soared by 162.11% to $167.5 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Cash from Investing Activities are $167.5 million (Q4 2025), $13.5 million (Q3 2025), and $26.3 million (Q2 2025).